Conservative Therapy Of Inflammatory Diseases Of Large Intenstine
Abstract
The target of research was the implementation of the comparative analysis of conservative therapy of preparation of basic therapy and also new methods of treatment (anticytokine therapy). Appointment of salofalk - in twos tablets (0, 5) 3-4 times a day per os, and also 2,0 gr in the form of a rectal enema unitary for a period of seven days, then had transferd the patients to reception 2,0 gr salofalk per os, allowed to achieve substantial improvement patients’ clinic-laboratory and endoscopic symptoms with a heavy intensification of ulcer colitis variation, providing full clinic-labaratory remissions achievements of disease at 8 (34 %) patients. In the Minister of the Uzbek Public Health of the Republican Science Coloproctological Center at 10 patients with the IDI have spent the therapy remicade, 7 of them had NUC and 3 patients had the Crohn's disease. Therefore, all patients no longer than on the first week after introduction of remicade had improvement of a course disease which was expressed in defering stool, extinction or reduction of pathological impurity in excrement and subsidence bellyaches. During colonoscopical inspection, in 12-18 weeks after the first infusion at 80% of the patients had observed disappearance of ulcers and erosion. In terms of 6 months of supervision of relapse of disease was not noted. All new directions in treatment of the IDI, apparently, are perspective, but while are proved only theoretically and had no practical development. Unique and enough effective and safe method at the IDI and already has clinical acknowledgement is remicade.
References
Belousova E.A. Ulcerous colitis and the Crohn's disease.-M.,Triada,2002.-254 p.
Belousova E.A., Morozova N.A., Nikitina N.V. Infliksimab (remicade) treatment in a refractory form the Crohn's disease//RMJ.-2005-T.7.#1.C.28-29.
Grigoryeva G. Moden status of nonspecific problem of ulserous colitis and the Crohn's disease. //Doctor.-1999.-C.7-10.
Navruzov C.N., Navruzov B.C. The Crohn's disease, 2009.- C.7-10.
Halif I.L. Remicade :the tretment of the Crohn's disease at the third illenium// Rus. mag. gastroenterol., gepotol. and coloproct.-2003.-3#.-62-65p.
Abreu M. T., Taylor K. D., Lin Y. C. Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn’s disease // Gastroenterology. – 2002. – V. 123. –N3. – P. 679-688.
Copyright information
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License (Creative Commons Attribution License 3.0 - CC BY 3.0) that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
info@cbuni.cz, www.cbuni.cz, ojs.journals.cz